Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ephedrine and Pioglitazone for BAT Enhancement
NCT02236962Unknown
- Start
- Apr 2012
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of ephedrine and pioglitazone in obesity, type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) (2 arms). Primary endpoint: Brown Adipose Tissue Activity at 3 years. Status: unknown.
02
Drugs
ephedrinepioglitazone
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT02236962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02236962.